The Zentalis Wee1 inhibitor, ZN-c3 , is a highly selective kinase inhibitor that is currently being evaluated in Ph. II clinical trials in adult women with recurrent or persistent uterine serous carcinoma (USC). The starting pyrazolopyrimidinone series was from the WO2013126656 patent, and while the molecule is similar to other kinase [...]
< 1 minute read
Oct. 6, 2021
ZN-c3: A Selective Wee1 Kinase Inhibitor
ZN-c3
selective oral Wee1 kinase inh. (300 mg QD) Ph. II candidate for uterine serous carcinoma from literature starting point Journal of Medicinal Chemistry Zentalis Pharmaceuticals, San Diego, CA, USA
Loading...
